Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, has scheduled a webcast for May 14, 2025, at 4:30 p.m. Eastern Time. During the webcast, the company will discuss its financial results for the first quarter ended March 31, 2025, and provide a business update.
The webcast will be accessible through the company's investor relations website, and a replay will be available for approximately 90 days following the event. Belite Bio specializes in developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Belite Bio (NASDAQ: BLTE), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per malattie degenerative della retina, ha programmato una webcast per il 14 maggio 2025 alle 16:30 ora orientale. Durante la trasmissione, l'azienda discuterà i risultati finanziari del primo trimestre terminato il 31 marzo 2025 e fornirà un aggiornamento sulle attività aziendali.
La webcast sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda e sarà disponibile una registrazione per circa 90 giorni dopo l'evento. Belite Bio si concentra nello sviluppo di nuovi trattamenti per malattie degenerative della retina con importanti bisogni medici insoddisfatti.
Belite Bio (NASDAQ: BLTE), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar terapias para enfermedades degenerativas de la retina, ha programado una transmisión en línea para el 14 de mayo de 2025 a las 4:30 p.m. hora del Este. Durante la transmisión, la compañía discutirá sus resultados financieros del primer trimestre finalizado el 31 de marzo de 2025 y ofrecerá una actualización del negocio.
La transmisión estará disponible a través del sitio web de relaciones con inversionistas de la empresa, y una repetición estará accesible aproximadamente por 90 días después del evento. Belite Bio se especializa en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina con necesidades médicas significativas no cubiertas.
Belite Bio (NASDAQ: BLTE)는 퇴행성 망막 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 2025년 5월 14일 오후 4시 30분(동부 표준시)에 웹캐스트를 예정하고 있습니다. 웹캐스트에서는 2025년 3월 31일로 종료된 1분기 재무 실적과 사업 현황에 대해 논의할 예정입니다.
웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접속할 수 있으며, 행사 후 약 90일 동안 다시보기 서비스가 제공됩니다. Belite Bio는 중대한 미충족 의료 수요가 있는 퇴행성 망막 질환에 대한 혁신적인 치료제 개발에 특화되어 있습니다.
Belite Bio (NASDAQ : BLTE), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les maladies dégénératives de la rétine, a programmé une webdiffusion pour le 14 mai 2025 à 16h30 heure de l'Est. Lors de cette webdiffusion, la société discutera de ses résultats financiers pour le premier trimestre clos le 31 mars 2025 et fournira une mise à jour commerciale.
La webdiffusion sera accessible via le site web des relations investisseurs de la société, et un replay sera disponible pendant environ 90 jours après l'événement. Belite Bio se spécialise dans le développement de nouveaux traitements pour les maladies dégénératives de la rétine présentant des besoins médicaux importants non satisfaits.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Therapien für degenerative Netzhauterkrankungen spezialisiert hat, hat eine Webcast für den 14. Mai 2025 um 16:30 Uhr Eastern Time angekündigt. Während des Webcasts wird das Unternehmen die Finanzergebnisse für das am 31. März 2025 beendete erste Quartal vorstellen und ein Geschäftsupdate geben.
Der Webcast ist über die Investor-Relations-Website des Unternehmens zugänglich, und eine Aufzeichnung wird etwa 90 Tage nach der Veranstaltung verfügbar sein. Belite Bio spezialisiert sich auf die Entwicklung neuartiger Therapeutika für degenerative Netzhauterkrankungen mit erheblichem ungedecktem medizinischem Bedarf.
- None.
- None.
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025.
Webcast Information
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/137642555
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When is Belite Bio (BLTE) hosting its Q1 2025 earnings webcast?
How can I access Belite Bio's Q1 2025 earnings webcast?
How long will the replay of Belite Bio's Q1 2025 earnings webcast be available?
What is Belite Bio's main business focus?
